Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells

Published:2016-01 Issue:2 Volume:370 Page:332-344
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Li Zhen,Jiang Ke,Zhu Xiaofang,Lin Guibin,Song Fei,Zhao Yongfu,Piao Yongjun,Liu Jiwei,Cheng Wei,Bi Xiaolin,Gong Peng,Song Zhiqi,Meng Songshu

Funder

National Science Foundation of China

Liaoning Natural Science Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference50 articles.

1. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma;Bollag;Nature,2010

2. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma;Shepherd;Curr. Oncol. Rep,2010

3. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N. Engl. J. Med,2011

4. Inhibition of mutated, activated BRAF in metastatic melanoma;Flaherty;N. Engl. J. Med,2010

5. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial;Falchook;Lancet,2012

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells;Frontiers in Cell and Developmental Biology;2024-06-14

2. Novel Pyrazole‐Chalcone Hybrids: Synthesis and Computational Insights Against Breast Cancer;Chemistry & Biodiversity;2024-06-11

3. Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy;Pharmaceutics;2024-04-11

4. Antitumorigenic effect of combination treatment with BRAF inhibitor and cisplatin in colorectal cancer in vitro and in vivo;2024-03-21

5. A Conversation with ChatGPT on Contentious Issues in Senescence and Cancer Research;Molecular Pharmacology;2024-03-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3